GlassScriptPhysician profile
Jason A Stienecker
NPI 1538455720
$397,080.62
in general payments reported to CMS, 2019-2025
32 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $16K · 2021: $49K · 2022: $60K · 2023: $71K · 2024: $78K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $165K · Travel and Lodging: $33K · Consulting Fee: $8,150 · Food and Beverage: $8,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,373.75 |
| Travel and Lodging | $32,670.53 |
| Consulting Fee | $8,150.00 |
| Food and Beverage | $8,136.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $344,698.79 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Olympus America INC. | $14,759.70 | 2019-2025 | Spiration Valve System, Spin Vision Video Processor |
| Merck Sharp & Dohme LLC | $12,288.61 | 2022-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $8,570.30 | 2019-2024 | Opsumit, Uptravi |
| Intuitive Surgical, INC. | $6,228.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,865.69 | 2019-2025 | Tezspire, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $3,085.98 | 2019-2024 | |
| Galvanize Therapeutics, INC | $614.99 | 2025 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $461.61 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.37 | 2019-2023 | Ofev |
| Glaxosmithkline, LLC. | $294.16 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Healthmyne, INC. | $132.71 | 2019 | |
| Genentech USA, INC. | $108.85 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $85.20 | 2019 | |
| Genzyme Corporation | $74.83 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $71.33 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $47.03 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $43.89 | 2019 | |
| Medtronic, INC. | $43.79 | 2021 | |
| Electromed, INC. | $42.94 | 2023-2024 | Smartvest |
| Insmed, INC. | $25.98 | 2019 | |
| Shire North American Group INC | $24.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.70 | 2019 | |
| Ethicon INC. | $23.68 | 2021 | |
| Axsome Therapeutics, INC. | $19.76 | 2023 | Sunosi |
| Vapotherm INC | $19.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.28 | 2022 | |
| Advanced Respiratory, INC | $15.46 | 2019 | |
| Circassia INC. | $13.83 | 2019 | |
| Amgen INC. | $12.84 | 2023 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $12.66 | 2021 | |
| Apria Healthcare LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Stienecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.